ADMA Biologics, Inc. ADMA

ADMA Biologics, Inc. es una empresa biotecnológica comercial. Desarrolla, fabrica y comercializa biológicos especializados derivados del plasma para el tratamiento y prevención de enfermedades infecciosas. Se dedica al desarrollo y comercialización de terapéuticos derivados del plasma humano. Sus pacientes incluyen individuos inmunocomprometidos que sufren de un trastorno de inmunodeficiencia subyacente e inmunosuprimidos por razones médicas. Su producto incluye BIVIGAM, un producto de Inmunoglobulina Intravenosa (IVIG) indicado para el tratamiento de Inmunodeficiencia Humoral Primaria (PI); ASCENIV, un producto de IVIG indicado para el tratamiento de PI, y Nabi-HB que está indicado para el tratamiento de la exposición aguda a sangre que contiene el antígeno de superficie de la Hepatitis B (HBsAg). Su subsidiaria ADMA BioCenters opera más de 10 instalaciones de recolección de plasma fuente en los Estados Unidos. Su segmento de Centros de Recolección de Plasma proporciona una parte de su plasma sanguíneo para la fabricación de sus productos.

• Zacks Investment Research 8 sept

  Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?

  While brokers give Adma Biologics an average recommendation of 2.00 (Buy) based on five firms' ratings, the article cautions that brokerage recommendations often have positive bias due to institutional vested interests. The company's Zacks Rank is #3 (Hold), as earnings estimates have remained unchanged, suggesting the stock may perform in line with the broader market in the near term.

  

• GlobeNewswire Inc. 9 ago

  BTU IMPORTANT DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Peabody Energy Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BTU

  Rosen Law Firm is encouraging investors who suffered losses exceeding $100,000 in Peabody Energy Corporation (BTU) to join a securities class action lawsuit. The lawsuit alleges that Peabody Energy provided misleading statements about its Centurion mine operations, with actual Q1 2026 output reaching only 250,000 tons versus previously estimated 700,000 tons. The lead plaintiff deadline is August 24, 2026. Similar class actions are also being pursued against ADMA Biologics and Microvast Holdings.

  

• GlobeNewswire Inc. 9 ago

  ADMA DEADLINE TOMORROW: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm – ADMA

  Rosen Law Firm reminds investors of the August 10, 2026 deadline to join a securities class action lawsuit against ADMA Biologics. The lawsuit alleges the company made materially false statements regarding undisclosed related party transactions, channel stuffing, and inadequate internal controls that artificially inflated revenue during the class period from August 9, 2024 to March 25, 2026.

  

• GlobeNewswire Inc. 7 ago

  ADMA 3-DAY DEADLINE ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– Hagens Berman

  ADMA Biologics is facing a securities fraud class action lawsuit alleging misrepresentations regarding financial condition, revenue recognition, and undisclosed related-party transactions. A short-seller report in March 2026 revealed channel stuffing and improper accounting practices, causing the stock to plunge 31.6% over two trading days. The lawsuit covers the period from August 9, 2024 to March 25, 2026, with a lead plaintiff deadline of August 10, 2026.

  

• GlobeNewswire Inc. 6 ago

  MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - ADMA

  ADMA Biologics is facing a securities class action lawsuit alleging the company made false statements regarding undisclosed related party transactions, channel stuffing schemes, and inadequate internal controls. A Culper Research report claimed ADMA's reported 20% growth in 2025 was artificially inflated, with actual revenue declining 3% when adjusted for extended payment terms. The stock declined over 16% following the report, and an additional 13% after a Cantor Fitzgerald downgrade. Investors with substantial losses can seek lead plaintiff status by Monday, August 10, 2026.